Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial

Few pieces of evidence have been published on the use of Apatinib Mesylate (AM) against EGFR-TKI resistance in lung adenocarcinoma (LA) patients. Here, we investigate the clinical efficacy and safety of AM in the treatment of advanced progressed epidermal growth factor receptor tyrosine kinase inhib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Fang, Ping, Zhang, Liqin, Zhang, Xianru, Yu, Jiawen, Sun, Jun, Jiang, Qi-an, Zha, Mingbao, Nesterova, Anastasia P., Cao, Hongbao
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6768876/
https://ncbi.nlm.nih.gov/pubmed/31570733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-50350-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars